研究者詳細 - 渡邉　豊彦

論文 - 渡邉　豊彦

分割表示 429 件中 421 - 429 件目／全件表示 >>

Basic and clinical studies on temafloxacin in urogenital infections 査読

Kazuhiro Hata, Toyohiko Watanabe, Tadasu Takenaka, Satoshi Uno, Toshihide Hayashi, Noriaki Ono, Hiromi Kumon, Hiroyuki Ohmori, Katsuichi Nanba, Katsuyoshi Kondo, Shin Irie, Tetsuzo Kaneshige

CHEMOTHERAPY 41 537 - 546 1993年

記述言語：英語掲載種別：研究論文（学術雑誌）

The penetration into prostatic fluid, antibacterial activity and clinical usefulness of temafloxacin (TMFX), a new quinolone, were studied. 1) The concentrations of TMFX in the prostatic fluid were 0.33, 0.71 and 0.66 μg/ml at 1, 2 and 4 hours after a single administration of 300 mg of TMFX, and the ratios to serum level (prostatic fluid/serum) were 0.32, 0.35 and 0.43, respectively. 2) We determined the MICs of TMFX against clinical isolates (209 strains of 14 species) from urinary tract infections, and compared them with those of ofloxacin (OFLX), ciprofloxacin (CPFX), enoxacin (ENX) and norfloxacin (NFLX). The antibacterial activity of TMFX was inferior to that of CPFX but almost equal to those of other control drugs. 3) The overall clinical efficacy rate, evaluated according to the criteria of the Japanese UTI Committee, was 100% (2/2) in acute uncomplicated cystitis and 69.2% (9/13) in chronic complicated UTI. Bacteriologically, 12 of 14 strains (85.7%) were eradicated. Two patients with chronic prostatitis were evaluated as good and fair by the doctors. 4) No drug-related side effects, including abnormal laboratory findings, were observed in any of the 17 cases. © 1993, Japanese Society of Chemotherapy. All rights reserved.

DOI： 10.11250/chemotherapy1953.41.Supplement5_537

Scopus

researchmap

Pharmacokinetics of vancomycin and dosage planning in patients with renal insufficiency 査読

Tadasu Takenaka, Toyohiko Watanabe, Toshihide Hayashi, Kazuhiro Hata, Noriaki Ono, Hiromi Kumon, Hiroyuki Ohmori, Tetsuzou Kaneshige, Katsuichi Nanba, Hiroyuki Omori

CHEMOTHERAPY 41 ( 10 ) 1079 - 1089 1993年

記述言語：英語掲載種別：研究論文（学術雑誌）

We assessed the pharmacokinetics and dosage regimen of vancomycin in patients with renal insufficiency. 1) Vancomycin (VCM), 500 mg, was administered to healthy volunteers and patients with varying degrees of impaired renal function by 60-minute drip infusion. Serum levels of VCM after a single dose were assayed by FPIA and urinary levels by bioassay. Pharmacokinetic parameters were determined using a two-compartment model. In healthy volunteers, mean T1/2(β) was 3.08h and mean β was 0.233/h. As the degree of renal insufficiency became more severe, T1/2(β) became more prolonged and β decreased. The mean 24-h urinary excretion rate was 96.3% in the healthy volunteers and decreased in accordance with the severity of the renal insufficiency. 2) To plan the dosage regimen, β was selected as a parameter which varied in accordance with the degree of impaired renal function as determined on the basis of creatinine clearance. The appropriateness of this regimen was confirmed in a multiple-dose study. © 1993, Japanese Society of Chemotherapy. All rights reserved.

DOI： 10.11250/chemotherapy1953.41.1079

Scopus

researchmap

Pharmacokinetics and dosage planning of cefozopran in patients with renal insufficiency 査読

Tadasu Takenaka, Toyohiko Watanabe, Toshihide Hayashi, Kazuhiro Hata, Noriaki Ono, Hiromi Kumon, Hiroyuki Ohmori, Katsuichi Nanba, Tetsuzou Kaneshige, Hiroyuki Ohmori

CHEMOTHERAPY 41 147 - 153 1993年

記述言語：英語掲載種別：研究論文（学術雑誌）

We investigated pharmacokinetics of cefozopran (CZOP), a new cephem antibiotic, in patients with renal insufficiency. Serum levels of CZOP after a single administration were assayed by HPLC and urinary levels by Bioassay. 1) 1.0g CZOP were administered to healthy volunteers and patients with varying degrees of impaired renal function by 30minutes drip infusion. Pharmacokinetic parameters were determined using a two-compartment model. In healthy volunteers, the mean values of T1/2 (β) was 2.20h and β was 0.321/h. As proceeded the renal insufficiency, T1/2 (β) was prolonged and β was decreased. The mean urinary excretion rate within 24h was 70.0% in healthy volunteers and decreased to 32.5% in Patients with severe renal insufficiency whose creatinine clearrance (Ccr) were below 30ml/min. 2) To plan a regimen, β was selected as the parameter which varied in accordance with the degree of impaired renal function as measured by Ccr. A recommended dosing regimen in patients with renal insufficiency was studied. © 1993, Japanese Society of Chemotherapy. All rights reserved.

DOI： 10.11250/chemotherapy1953.41.Supplement4_147

Scopus

researchmap

Basic and clinical studies on loracarbef in the urological field 査読

Toyohiko Watanabe, Tadasu Takenaka, Toshihide Hayasi, Kazuhiro Hata, Noriaki Ono, Hiromi Kumon, Hiroyuki Ohmori

CHEMOTHERAPY 41 310 - 317 1993年

記述言語：英語掲載種別：研究論文（学術雑誌）

We studied the antibacterial activity and efficacy of loracarbef (LCBF), a new carbacephem antibiotic, in the urological field. 1) Antibacterial activity: The MICs of LCBF were measured against 205 clinical isolates of 14 species from urinary tract infections and compared with those of cefixime (CFIX), cefteram pivoxil (CFTM-PI) and cefaclor (CCL). In general, the antibacterial activities of LCBF were almost equal to those of CCL. 2) Clinical efficacy in complicated urinary tract infection was evaluated according to the criteria of the Japanese UTI Committee. The clinical response in 8 evaluable patients was considered excellent in 4, moderate in 3 and poor in 1. Seven (87.5%) of 8 strains isolated were eradicated. 3) The concentration of LCBF in expressed prostatic secretion (EPS) was studied after oral administration of the drug at a dose of 200 mg. Four hours after the administration of LCBF, the concentration in EPS reached 0.48±0.16 μg/ml (n=3), and the ratio between serum and EPS was 0.28±0.12. 4) Side effects: Diarrhea and abdominal pain were observed in 1 patient. Both symptoms were mild and transient. Based on the above findings, it is considered that LCBF is useful in the treatment of urinary tract infection. © 1993, Japanese Society of Chemotherapy. All rights reserved.

DOI： 10.11250/chemotherapy1953.41.Supplement3_310

Scopus

researchmap

慢性前立腺炎に対する経直腸的温熱療法の臨床的検討

公文裕巳, 小野憲昭, 宇埜智, 林俊秀, 畠和宏, 竹中皇, 渡辺豊彦, 大森弘之

日本泌尿器科學會雑誌 84 ( 2 ) 265 - 271 1993年

出版者・発行元：社団法人日本泌尿器科学会

延べ36例の慢性非細菌性・非クラミジア性前立腺炎および前立腺痛患者を対象にマイクロウェーブによる経直腸的前立腺温熱療法を試みた. 治療は週1回1時間で5週間, 前立腺組織内温度を43℃に設定して行った. 全例長期の経過を有する前治療無効症例であった. 治療効果は自覚症状に対する効果および前立腺液中膿球に対する効果で総合的に判定した. 総合臨床効果では, 著効11例 (30.6%), 有効8例 (22.2%), やや有効8例 (22.2%), 無効9例 (25.0%) であった. 副作用に関しては, 肛門部痛を2例, 血精液症を1例, 血尿を1例に認めたが, 全例治療を中断ないし中止することなく継続治療が可能であった. 以上の成績は, 従来の治療に対して反応性に乏しい慢性前立腺炎に対する経直腸的温熱療法の有用性を示すものであった.

DOI： 10.5980/jpnjurol1989.84.265

CiNii Article

CiNii Books

researchmap

その他リンク： http://search.jamas.or.jp/link/ui/1993200743

Basic and clinical studies on S-1108 in urinary tract infections

Noriaki Ono, Toyohiko Watanabe, Tadasu Takenaka, Toshihide Hayashi, Kazuhiro Hata, Hiromi Kumon, Hiroyuki Ohmori, Katsuiehi Nanba, Yoshikatsu Kondou, Teruhisa Ohhashi, Teruaki Akaeda

CHEMOTHERAPY 41 448 - 455 1993年

記述言語：英語掲載種別：研究論文（学術雑誌）

We studied the antibacterial activity and efficacy of S-1108, a new cephem antibiotic, in urinary tract infections. 1) Antibacterial activity : The MICs of S-1006 were measured against 202 clinical isolates of 14 species from urinary tract infections and compared with those of cefaclor (CCL), cefixime (CFIX) and cefteram (CFTM). In general, the antibacterial activity of S-1006 was almost equal to that of CFIX and CFTM, but superior to that of CCL. 2) Clinical efficacy : According to the criteria of the Japanese UTI Committee, the overall clinical efficacy rate was 84.2% (16/19) for chronic complicated UTI. Bacteriologically, 21 of the 22 strains isolated (95.4%) were eradicated. 3) Side effects : No clinical adverse reactions and no abnormal laboratory findings were observed. © 1993, Japanese Society of Chemotherapy. All rights reserved.

DOI： 10.11250/chemotherapy1953.41.Supplement1_448

Scopus

researchmap

Renal cyst with cholesterol crystals: A case report

T. Watanabe, Y. Nasu, H. Kumon, H. Ohmori

Nishinihon Journal of Urology 55 ( 11 ) 1658 - 1661 1993年

Mucinous adenocarcinoma of the prostate: A case report

T. Watanabe, K. Hata, Y. Nasu, H. Ohmori

Nishinihon Journal of Urology 55 ( 11 ) 1654 - 1657 1993年

Basic and clinical studies of cefozopran in the urological field

Kazuhiro Hata, Toyohiko Watanabe, Tadasu Takenaka, Toshihide Hayashi, Noriaki Ono, Hiromi Kumon, Hiroyuki Ohmori, Katsuyoshi Kondo, Katsuichi Nanba, Teruaki Akaeda, Nobuyuki Akazawa, Nobuyuki Akazawa, Yasuhiro Katayama

CHEMOTHERAPY 41 309 - 318 1993年

記述言語：英語掲載種別：研究論文（学術雑誌）

We studied the antibacterial activity and clinical efficacy of cefozopran (CZOP), a new cephalosporin antibiotic, in the urological field. 1) Antibacterial activity : We measured MICs of CZOP against clinical isolates (206 strains of 14 species) from urinary tract infections, and compared them with those of imipenem (IPM), ceftazidime (CAZ), latamoxef, and cefoperazone. In general, the antibacterial activities of CZOP were almost equal to those of CAZ but superior to those of other control cephems, and slightly inferior to those of IPM. 2) Clinical efficacy: According to the criteria of the Japanese UTI Committee, the overall clinical efficacy rate was 78.7 % (37/47) for chronic complicated UTI. Bacteriologically, 41 of 47 strains (87.2 %) were eradicated. As regards 2 cases of acute bacterial prostatitis, overall clinical efficacy was moderate and strains were eradicated in both cases. 3) Side effects: No clinical side effects were observed. Concerning laboratory findings, transient elevation of GOT and GPT were noted in two cases, eosinophilia in one case and a transient elevation of s-Cr in one case. © 1993, Japanese Society of Chemotherapy. All rights reserved.

DOI： 10.11250/chemotherapy1953.41.Supplement4_309

Scopus

researchmap

　前のページ - 次のページ　

<渡邉 豊彦>

論文 - 渡邉 豊彦

<渡邉　豊彦>

論文 - 渡邉　豊彦